Phase I Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies.

Trial Profile

Phase I Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs MVT 5873 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Colon cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors MabVax Therapeutics
  • Most Recent Events

    • 31 Oct 2017 According to a MabVax Therapeutics media release, the company is currently enrolling an additional cohort of patients at the 0.125mg/kg cohort and expects to report on additional data near the end of this year.
    • 31 Oct 2017 Results published in the MabVax Therapeutics Media Release
    • 31 Oct 2017 According to a MabVax Therapeutics media release, data from this trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top